Table 2.
IC50 values (μM) of PI-083 and Bortezomib for cell viability measured by MTT assay in different cancer and normal cell lines
| Cancer | Cell line | 24 h | 72 h | ||
|---|---|---|---|---|---|
| PI-083 | Bortezomib | PI-083 | Bortezomib | ||
| Breast | MCF-7 | 4.5 ± 0.82 * (0.0001) | >30 | 2.2 ± 1.1 * (0.04) | 8.6 ± 1.41 |
| MCF-10A | 17± 0.86 | >30 | 4.2 ± 2.1 | 0.15 ± 0.074 * (0.0015) | |
| Pancreas | C7-Kras | 2.4 ± 0.23 * (0.0013) | >30 | 1.9 ± 0.2 * (0.007) | 0.028 ± 0.006 (0.51) |
| C7 | 5.1 ± 0.53 | >30 | 4.2 ± 1.6 | 0.032 ± 0.001 | |
| Ovary | T80-Hras | 1.5 ± 0.57 * (0.017) | >30 | 2.1 ± 0.4 | 0.024 ± 0.01 |
| T80 | 2.7 ± 0.53 | >30 | 1.7 ± 0.39 (0.15) | 0.014 ± 0.001 (0.29) | |
| Prostate | DU-145 | 8.6 ± 0.63 | >30 | 5.0 ± 0.72 | 0.025 ± 0.002 |
| Prostate | LNCaP | 14 ± 2.8 | >30 | 5.2 ± 1.1 | 0.057 ± 0.004 |
| Lung | CaLu-1 | 7.3 ± 0.43 | >30 | 4.9 ± 1.2 | 0.022 ± 0.002 |
| Lung | A549 | 41 ± 17 | >30 | 11 ± 6.7 | 0.41 ± 0.07 |
| Multiple Myeloma | U266 | 23 ± 1.7 | >30 | 7.0 ± 1.5 | 0.012 ± 0.003 |
| Multiple Myeloma | RPMI-8226 | 7.4 ± 0.38 | 0.049 ± 0.025 | 10 ± 4.0 | 0.026 ± 0.003 |
The values given are the means of 3 to 5 experiments ± standard deviation. Statistically significant differences between cancer and non-transformed cells were established by performing a t-test
*
p < 0.05.